Oncotarget

Vol 1, No 7

November 2010

View Archive »

Order a Reprint

About The Cover

Fusion of 3T3 or p53-/- 3T3 fibroblasts. At 6 h after fusion, the cells were fixed and centrosomes were visualized with immunostaining for γ-tubulin. The nuclei were stained with DAPI. See Chui Chui Ho et al. The requirement of p53 for maintaining chromosomal stability during tetraploidization (pp 583).

Table of Contents

Commentaries

Beta-adrenergic signaling, a novel target for cancer therapy?

Beta-adrenergic signaling, a novel target for cancer therapy?

https://doi.org/10.18632/oncotarget.182

Hildegard M. Schuller
466-469
PDF  |  HTML  |  Order a Reprint

A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53

A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53

https://doi.org/10.18632/oncotarget.183

Robert I. Glazer
470-471
PDF  |  HTML  |  Order a Reprint

Reviews

Refractory chronic lymphocytic leukemia – new therapeutic strategies

Refractory chronic lymphocytic leukemia – new therapeutic strategies

https://doi.org/10.18632/oncotarget.184

Andrea Schnaiter,  and Stephan Stilgenbauer
472-482
Abstract  |  PDF  |  HTML  |  Order a Reprint

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)

https://doi.org/10.18632/oncotarget.185

Peter Valent, Attilio Orazi, Guntram Büsche, Annette Schmitt-Gräff, Tracy I. George, Karl Sotlar, Berthold Streubel, Christine Beham-Schmid, Sabine Cerny-Reiterer, Otto Krieger, Arjan van de Loosdrecht, Wolfgang Kern, Kiyoyuki Ogata, Friedrich Wimazal, Judit Csomor, Judit Várkonyi, Wolfgang R. Sperr, Martin Werner, Hans Kreipe,  and Hans-Peter Horny
483-496
Abstract  |  PDF  |  HTML  |  Order a Reprint

EGFR-mutated lung cancer: a paradigm of molecular oncology

EGFR-mutated lung cancer: a paradigm of molecular oncology

https://doi.org/10.18632/oncotarget.186

Zhenfeng Zhang, Amy L. Stiegler, Titus J. Boggon, Susumu Kobayashi,  and Balazs Halmos
497-514
Abstract  |  PDF  |  HTML  |  Order a Reprint

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

https://doi.org/10.18632/oncotarget.187

Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King,  and Jennifer Spratlin
515-529
Abstract  |  PDF  |  HTML  |  Order a Reprint

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

https://doi.org/10.18632/oncotarget.188

Ben Markman, Rodrigo Dienstmann,  and Josep Tabernero
530-543
Abstract  |  PDF  |  HTML  |  Order a Reprint

The pursuit of oncotargets through understanding defective cell regulation

The pursuit of oncotargets through understanding defective cell regulation

https://doi.org/10.18632/oncotarget.189

Meng Qiao, Qian Shi,  and Arthur B. Pardee
544-551
Abstract  |  PDF  |  HTML  |  Order a Reprint

Targeting Metabolic Remodeling in Glioblastoma Multiforme

Targeting Metabolic Remodeling in Glioblastoma Multiforme

https://doi.org/10.18632/oncotarget.190

Amparo Wolf, Sameer Agnihotri,  and Abhijit Guha
552-562
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells

Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells

https://doi.org/10.18632/oncotarget.191

Joshua C. Curtin,  and Matthew V. Lorenzi
563-577
Abstract  |  PDF  |  HTML  |  Order a Reprint

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia

https://doi.org/10.18632/oncotarget.192

Antonio Sacco, Aldo Roccaro,  and Irene M. Ghobrial
578-582
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

The requirement of p53 for maintaining chromosomal stability during tetraploidization

The requirement of p53 for maintaining chromosomal stability during tetraploidization

https://doi.org/10.18632/oncotarget.193

Chui Chui Ho, Pok Man Hau, Miriam Marxer,  and Randy Y.C. Poon
583-595
Abstract  |  PDF  |  HTML  |  Order a Reprint

The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling

The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling

https://doi.org/10.18632/oncotarget.194

Shaheen Sikandar, Diana Dizon, Xiling Shen, Zuomei Li, Jeffery Besterman,  and Steven M. Lipkin
596-605
Abstract  |  PDF  |  HTML  |  Order a Reprint

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

https://doi.org/10.18632/oncotarget.195

Rachael Elizabeth Hawtin, David Elliot Stockett, Oi Kwan Wong, Thomas Helleday,  and Judith Ann Fox
606-619
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Sumoylation of Vimentin354 Is Associated with PIAS3 Inhibition of Glioma Cell Migration

Sumoylation of Vimentin354 Is Associated with PIAS3 Inhibition of Glioma Cell Migration

https://doi.org/10.18632/oncotarget.196

Liming Wang, Jian Zhang, Sipra Banerjee, Laura Barnes, Venkateswara Sajja, Yiding Liu, Baochuan Guo, Yuping Du, Mukesh K. Agarwal, David N. Wald, Qin Wang,  and Jinbo Yang
620-627
Abstract  |  PDF  |  HTML  |  Order a Reprint

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

https://doi.org/10.18632/oncotarget.197

Desmond G. Powe, Melanie J. Voss, Kurt S. Zänker, Hany O. Habashy, Andrew R. Green, Ian O. Ellis,  and Frank Entschladen
628-638
Abstract  |  PDF  |  HTML  |  Order a Reprint

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

https://doi.org/10.18632/oncotarget.198

Bhavya Rao, Ingeborg M.M. van Leeuwen, Maureen Higgins, Johanna Campbell, Alastair M. Thompson, David P. Lane,  and Sonia Lain
639-650
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Research Perspectives

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget

https://doi.org/10.18632/oncotarget.199

Inti Zlobec,  and Alessandro Lugli
651-661
Abstract  |  PDF  |  HTML  |  Order a Reprint

Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors

Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors

https://doi.org/10.18632/oncotarget.200

Giulia Taraboletti, Marco Rusnati, Laura Rusnati,  and Giorgio Ragona
662-673
Abstract  |  PDF  |  HTML  |  Order a Reprint

Wnt/Β-Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer

Wnt/Β-Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer

https://doi.org/10.18632/oncotarget.201

Yongyi Wang, Marten van der Zee, Riccardo Fodde,  and Leen J. Blok
674-684
Abstract  |  PDF  |  HTML  |  Order a Reprint

Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction

Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction

https://doi.org/10.18632/oncotarget.202

Hiroyuki Inuzuka, Hidefumi Fukushima, Shavali Shaik,  and Wenyi Wei
685-690
Abstract  |  PDF  |  HTML  |  Order a Reprint


Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC